Sirolimus-Based Immunosuppressive Regimens in Renal Transplantation: A Systemic Review

被引:13
|
作者
Zhao, D. Q. [1 ]
Li, S. W. [1 ]
Sun, Q. Q. [1 ]
机构
[1] Sun Yat Sen Univ, Kidney Transplantat Dept, Affiliated Hosp 3, Guangzhou 510275, Guangdong, Peoples R China
关键词
EARLY CYCLOSPORINE WITHDRAWAL; LONG-TERM TRIAL; CALCINEURIN INHIBITOR-MINIMIZATION; EARLY STEROID WITHDRAWAL; DE-NOVO SIROLIMUS; MYCOPHENOLATE-MOFETIL; KIDNEY-TRANSPLANTATION; RANDOMIZED-TRIAL; OPEN-LABEL; TACROLIMUS/MYCOPHENOLATE MOFETIL;
D O I
10.1016/j.transproceed.2016.01.002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Sirolimus (SRL)-based immunosuppressive regimens have been used for preventing rejection after kidney transplantation. This review analyzes their merits and demerits compared with other conventional regimes from the aspects of acute rejection rate, graft function, as well as patient/graft survival rates. In general, SRL is mostly recommended to be used as conversion therapy from calcineurin inhibitor (CNI) after kidney transplantation in most studies. Minimization or withdrawal of cyclosporine A (CsA) could also be considered when it was combined with SRL. SRL can replace mycophenolate mofetil (MMF), and the CNI dose should be reduced appropriately in this setting. Quadruple maintenance regimens containing SRL need future study to clarify their superiority. De novo use of low-dose CNI combined with SRL has no apparent merits and thus is not recommended. De novo use of standard-dose CNI combined with SRL followed by maintenance, de novo use of CNI-free regimens, as well as SRL use in delayed graft function (DGF) patients who spare antibody induction and postpone CNI administration should also be avoided. SRL supports steroids withdrawal after kidney transplantation, and SRL combined with tacrolimus is recommended in this setting. Loading dose is recommended when initiating SRL treatment and its trough blood level should be routinely monitored.
引用
收藏
页码:3 / 9
页数:7
相关论文
共 50 条
  • [21] The ORION Study: Comparison of Two Sirolimus-Based Regimens versus Tacrolimus and Mycophenolate Mofetil in Renal Allograft Recipients
    Flechner, S. M.
    Glyda, M.
    Cockfield, S.
    Grinyo, J.
    Legendre, Ch.
    Russ, G.
    Steinberg, S.
    Wissing, K. M.
    Tai, S. S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 (08) : 1633 - 1644
  • [22] Optimizing the clinical utility of sirolimus-based immunosuppression for kidney transplantation
    Tedesco-Silva, Helio
    del Carmen Rial, Maria
    Cruz Santiago, Jose
    Mazzali, Marilda
    Pacheco-Silva, Alvaro
    Torres, Rodolfo
    CLINICAL TRANSPLANTATION, 2019, 33 (02)
  • [23] Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients
    Morard, Isabelle
    Dumortier, Jerome
    Spahr, Laurent
    Hadengue, Antoine
    Majno, Pietro
    Morel, Philippe
    Mentha, Gilles
    Giostra, Emiliano
    LIVER TRANSPLANTATION, 2007, 13 (05) : 658 - 664
  • [24] Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma
    Zimmerman, Michael A.
    Trotter, James F.
    Wachs, Michael
    Bak, Tom
    Campsen, Jeffrey
    Skibba, Afshin
    Kam, Igal
    LIVER TRANSPLANTATION, 2008, 14 (05) : 633 - 638
  • [25] Switch to Sirolimus-based immunosuppresion in stable renal transplant recipients
    Nseir, G.
    Venetz, J. -P
    Hadaya, K.
    Buhler, L.
    Martin, P-Y
    Pascual, M.
    SWISS MEDICAL WEEKLY, 2008, 138 (47-48) : 18S - 18S
  • [26] Sirolimus-based rescue therapy after rejection in liver transplantation
    Llado, Laura
    Fabregat, Joan
    Castellote, Jose
    Ramos, Emilio
    Torras, Jaume
    Serrano, Teresa
    Figueras, Joan
    Rafecas, Antoni
    CLINICAL TRANSPLANTATION, 2009, 23 (01) : 89 - 95
  • [27] Sirolimus-based immunosuppresive protocol for calcineurin sparing in liver transplantation
    Heffron, TG
    Smallwood, GA
    Davis, L
    Martinez, E
    Stieber, AC
    TRANSPLANTATION PROCEEDINGS, 2002, 34 (05) : 1522 - 1523
  • [28] Conversion from a calcineurin inhibitor to a sirolimus-based therapy after renal transplantation - An update of existing recommendations
    Arns, W.
    Budde, K.
    Eitner, F.
    Gwinner, W.
    Hugo, C.
    Pressmar, K.
    Weimann, A.
    Witzke, O.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2011, 136 (49) : 2554 - 2559
  • [29] RENAL-TRANSPLANTATION IN BLACKS - IMPACT OF IMMUNOSUPPRESSIVE REGIMENS
    SUMRANI, NB
    HONG, JH
    HANSON, P
    BUTT, KMH
    TRANSPLANTATION PROCEEDINGS, 1989, 21 (06) : 3943 - 3945
  • [30] CYCLOSPORINE AND IMMUNOSUPPRESSIVE REGIMENS IN RENAL-TRANSPLANTATION - REPLY
    HALL, BM
    NEW ENGLAND JOURNAL OF MEDICINE, 1988, 319 (19): : 1288 - 1288